Posted by Michael Wonder on 21 Mar 2026
Toward greater transparency at the FDA - now is the time to act
18 March 2026 - The US FDA has generally sought to uphold the highest standards of scientific rigour in its regulation of medical products, tobacco, and food, but has at times been faulted for being inadequately transparent in its processes and decision-making.
Experts in government and institutional behaviour agree that greater agency openness strengthens public trust, improves accountability, and fosters innovation.
In this Viewpoint, we consider the FDA’s track record as it relates to transparency and what the future holds.
